NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

ABA-101 in Participants With Progressive Multiple Sclerosis

Active Not RecruitingPhase 1

Sponsor: Abata Therapeutics

Conditions: Progressive Multiple Sclerosis

Interventions: ABA-101

Countries: United States

This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis. It is the first study of this treatment in humans. After safety is demonstrated with a low dose of ABA-101, a higher dose will be evaluated.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Is ≥18 years old at signing of consent.
* Has a diagnosis of MS per the 2017 revised McDonald criteria.
* Has documented evidence of progression of disability independent of MS relapse activity (clinical or radiographic).
* Expresses the HLA that matches the TCR restriction.
* Presence of a radiographic biomarker of CNS inflammation as identified by MRI.
* Meets Expanded Disability Status Scale (EDSS) criteria.
* Meets the nine-hole peg test (9HPT) criteria.

Exclusion Criteria:

* Presents with clinical or radiographic evidence of relapse within 24 months prior to or at Screening.
* Is considered by the Investigator to be immunocompromised.
* Current treatment with disease-modifying therapies (DMTs).

Locations (3)

Baltimore, Maryland, United States
New Brunswick, New Jersey, United States
Cleveland, Ohio, United States